It has been showed that the serum ANGPTL4 level in RCC patients were higher than the level in patients with other types of solid tumor, such as bladder cancer, breast cancer, gastrointestinal cancer and lung adenocarcinoma, suggesting that the serum ANGPTL4 may be a diagnostic and prognostic biomarker for RCC [61]. This evidence concerns the gene ANGPTL4 and breast cancer.